FREQUENCY OF HER2 OVEREXPRESSION IN METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Main Article Content
Keywords
her2 overexpression, metastatic disease, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma
Abstract
Objectives: To assess the frequency of her2 overexpression in metastatic gastric and gastroesophageal junction adenocarcinoma
Study-Design: Cross Sectional survey
Place & Duration of Study: “Kuwait Teaching Hospital, Peshawar,” from May 2023 to December 2023.
Methodology: Total of 200 patients diagnosed with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma and metastatic disease were included in this study. Biopsy samples were taken and Her2 expression was assessed.
Results: - Out of the total 200 patients included, the average age of enrolled patients was 51.07 +11.85 years. There were 93 (46.5%) males and 107 (53.5%) females. Out of 200 cases, 96 (48.0%) had gastric adenocarcinoma while 104 (52.0%) had gastroesophageal junction adenocarcinoma. Out of 200 patients, her2 expression was positive in 49 (24.5%) cases.
Conclusion: The conclusion of this study is that patients with metastatic gastric and gastroesophageal junction adenocarcinoma, the presence of her2 expression is a common finding.
References
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
4. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World journal of gastroenterology: WJG. 2014;20(16):4483.
5. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, et al. Cancer mortality in India: a nationally representative survey. The Lancet. 2012;379(9828):1807-16.
6. Cats A, Jansen EP, van Grieken NC, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The lancet oncology. 2018;19(5):616-28.
7. Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet. 2019;393(10184):1948-57.
8. Ai D, Zhu H, Ren W, Chen Y, Liu Q, Deng J, et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. Journal of thoracic disease. 2017;9(9):3023.
9. Verstegen MH, Harker M, van de Water C, van Dieren J, Hugen N, Nagtegaal ID, et al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J Gastroenterol. 2020;26(39):6037-46.
10. Coutzac C, Funk-Debleds P, Cattey-Javouhey A, Desseigne F, Guibert P, Marolleau P, et al. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new? Bulletin du Cancer. 2023;110(5):552-9.
11. Kaur A, Dasanu CA. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert opinion on pharmacotherapy. 2011;12(16):2493-503.
12. Tong Z-J, Shi N-Y, Zhang Z-J, Yuan X-D, Hong X-M. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis. Bioscience reports. 2017;37(4):BSR20170121.
13. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22(19):4619-25.
14. Roy PS, Nyodu T, Hazarika M, Saikia BJ, Bhuyan C, Inamdar A, et al. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population. Asian Pac J Cancer Prev. 2019;20(4):1139-45.
15. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer and Metastasis Reviews. 2015;34:157-64.
16. He C, Bian X-Y, Ni X-Z, Shen D-P, Shen Y-Y, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World Journal of Gastroenterology: WJG. 2013;19(14):2171.
17. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Applied immunohistochemistry & molecular morphology: AIMM. 2012;20(1):13.
18. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagnostic pathology. 2013;8:1-7.
19. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World Journal of gastroenterology. 2016;22(19):4619.
20. Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Critical reviews in oncology/hematology. 2012;82(3):310-22.
21. Lei Y-y, Huang J-y, Zhao Q-r, Jiang N, Xu H-m, Wang Z-n, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World journal of surgical oncology. 2017;15(1):1-7.
22. Abdel-Salam R, El-Hawary A, Mohamed M, Gamil T. Immunohistochemical expression of Her2/neu in gastric carcinomas in Egyptian patients. J Clin Pathol Diagn. 2018;1(1):1-6.
23. Van Cutsem E, Bang Y-J, Feng-Yi F, Xu JM, Lee K-W, Jiao S-C, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric cancer. 2015;18:476-84.
24. Sheng W, Huang D, Ying J, Lu N, Wu H, Liu Y, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Annals of oncology. 2013;24(9):2360-4.
25. Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PloS one. 2013;8(11):e80290.
26. Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Annals of surgical oncology. 2003;10:234-41.
27. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18:691-7.
28. Fisher SB, Fisher KE, Squires MH, 3rd, Patel SH, Kooby DA, El-Rayes BF, et al. HER2 in resected gastric cancer: Is there prognostic value? J Surg Oncol. 2014;109(2):61-6.
29. Shen GS, Zhao JD, Zhao JH, Ma XF, Du F, Kan J, et al. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. World J Gastroenterol. 2016;22(23):5406-14.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Bilal Ahmad
Consultant Oncologist, Kuwait Teaching Hospital, Peshawar - Pakistan
Dr Assam Ahmad
Registrar Medical, Oncology Unit, Allied Hospital, Abbottabad - Pakistan
Dr Hafsa Fayyaz
Medical Officer, PIMS, Islamabad - Pakistan
Dr Sohail Ahmad
Specialist Registrar Oncology, Hayatabad Medical Complex. Peshawar - Pakistan
Dr Ummarah Riaz
Consultant Gastroenterologist, Ayub Teaching Hospital, Abbottabad - Pakistan
Dr Jahan Sardar
Assistant Professor Medicine, Kuwait Teaching Hospital, Peshawar - Pakistan